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OBJECTIVE — Risk prediction models obtained in samples from the general population do
not perform well in type 2 diabetic patients. Recently, 5-year risk estimates were proposed as
beingmoreaccuratethan10-yearriskestimates.Thisstudypresentsadiabetes-speciﬁcequation
for estimation of the absolute 5-year risk of ﬁrst incident fatal/nonfatal cardiovascular disease
(CVD) in type 2 diabetic patients with use of A1C and clinical characteristics.
RESEARCH DESIGN AND METHODS — The study was based on 11,646 female and
male patients, aged 18–70 years, from the Swedish National Diabetes Register with 1,482 ﬁrst
incident CVD events based on 58,342 person-years with mean follow-up of 5.64 years.
RESULTS — This risk equation incorporates A1C, as in the UK Prospective Diabetes Study
riskengine,andseveralclinicalcharacteristics:onsetageofdiabetes,diabetesduration,sex,BMI,
smoking, systolic blood pressure, and antihypertensive and lipid-reducing drugs. All predictors
included were associated with the outcome (P  0.0001, except for BMI P  0.0016) with Cox
regression analysis. Calibration was excellent when assessed by comparing observed and pre-
dicted risk. Discrimination was sufﬁcient, with a receiver operator curve statistic of 0.70. Mean
5-yearriskofCVDinallpatientswas12.07.5%,whereas54%ofthepatientshada5-yearrisk
10%.
CONCLUSIONS — This more simpliﬁed risk equation enables 5-year risk prediction of
CVD based on easily available nonlaboratory predictors in clinical practice and A1C and was
elaborated in a large observational study obtained from the normal patient population aged up
to 70 years.
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E
stimates of the risk for cardiovascu-
lar disease (CVD) can be used as
prognostic information and support
for the choice of therapeutic strategies for
individual patients. Several risk models
have been developed in recent years. The
Framingham (1), Systematic Coronary
Risk Evaluation (SCORE) (2), and Diabe-
tes Epidemiology: Collaborative Analysis
of Diagnostic Criteria in Europe
(DECODE)(3)riskmodels,inwhichtype
2diabeticpatientsarerepresentedassub-
groups of the populations studies, do not
include A1C and diabetes duration as
continuous risk factor variables. Further-
more, these models did not provide reli-
able risk estimates of fatal CVD in type 2
diabetic patients, as demonstrated in a re-
cent review (4).
Risk models optimized for type 2 di-
abetes are of special importance, as type 2
diabetic patients have a two to four times
higher CVD risk than the nondiabetic
population (5). The UK Prospective Dia-
betes Study (UKPDS) risk engine is a dia-
betes-speciﬁc model for estimation of the
absolute 10-year risk of myocardial in-
farction (6), stroke (7), and CVD (8) in
patients with newly detected type 2 dia-
betes with onset age up to 65 years and
includes A1C and diabetes duration as
risk factor variables, as well as systolic
blood pressure, smoking, total choles-
terol, and HDL cholesterol. However, as
also stated by the UKPDS, there is a need
for risk prediction models that are easy to
useindailyclinicalpracticeandarebased
on large surveys obtained from the gen-
eral type 2 diabetic population, reﬂect-
ing the normal patient clientele with
various durations of diabetes. Recently,
5-year estimates of risk were proposed
as being more accurate than 10-year
risk estimates (9).
The aim of this study was to analyze
the association between several baseline
predictor variables and ﬁrst incident fatal
or nonfatal CVD in type 2 diabetic pa-
tients. Data from the Swedish National
Diabetes Register (NDR) were used,
linked with the Swedish Cause of Death
and Hospital Discharge Registers to
identify CVD events. We also intended
to present a new risk equation for esti-
mation of the absolute 5-year risk of
CVD, based on A1C and several non-
laboratory clinical characteristics
within the NDR as predictors.
RESEARCH DESIGN AND
METHODS— The Swedish NDR was
initiated in 1996 as a tool for local quality
assuranceindiabetescare.Annualreport-
ing to the NDR is carried out by trained
physicians and nurses via the Internet or
via clinical records databases, with infor-
mation collected during patient visits at
hospital outpatient clinics and primary
health care centers nationwide. All pa-
tients included have agreed by informed
consent to register before inclusion. The
present study was approved by the re-
gional ethics committee at the University
of Gothenburg. Reports concerning
trends in risk factor control in the NDR,
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NDR and Swedish diabetes care, were
published previously (10–14).
This observational study consists of
11,646 female and male type 2 diabetic
patients from the NDR, with an age span
of 18 to 70 years and no previous CVD.
All subjects with data available for ana-
lyzed variables at baseline were included
and were followed prospectively from
1998 to 2003 for an analysis of the asso-
ciation between nine baseline risk predic-
tors and ﬁrst incident fatal or nonfatal
CVD. The deﬁnition of type 2 diabetes
was treatment with 1) diet only, 2) oral
hypoglycemic agents only, or 3) insulin
only or combined with oral agents, and
onset age of diabetes 40 years. Only 1
and 3%, respectively, had onset age 30
years and 40 years. Another sample of
3,068 type 2 diabetic patients was also
included (aged 18–70 years and no pre-
vious CVD), comprising all patients
newly registered in the NDR 1999, with 4
years of follow-up to 2003.
Examinations at baseline
Clinical characteristics at baseline were
type of hypoglycemic treatment, age, dia-
betesduration,sex,weight,height,smok-
ing, systolic blood pressures, and use of
antihypertensive and lipid-lowering
drugs. BMI was calculated as weight in
kilograms divided by the square of height
in meters. The Swedish standard for
blood pressure recording used in the
NDR is the mean value of two supine
readings (Korotkoff 1–5) with a cuff of
appropriatesize.Asmokerwasdeﬁnedas
a patient smoking one or more cigarettes
per day, an individual who smoked to-
bacco using a pipe, or an individual who
had stopped smoking within the past 3
months.
Laboratory analyses of A1C were per-
formed at local laboratories, and nation-
wide quality assurance is assessed by
regular calibration with the high-
performance liquid chromatography
Mono-S method. In this study, all A1C
values were converted to the Diabetes
Control and Complication Trial (DCCT)
standard values using the following for-
mula:A1C(DCCT)0.923A1C(Mo-
noS)  1.345; R
2  0.998 (15).
Follow-up and deﬁnition of end
point
All patients, who were free of CVD at
baseline, were followed from 1998 to
2003, until the ﬁrst incident CVD event,
death, or 31 December 2003. The end
point was fatal or nonfatal CVD, deﬁned
as coronary heart disease (CHD) or
stroke, whichever came ﬁrst. Fatal CHD
wasdeﬁnedasfatalischemicheartdisease
(ICD-10 codes I20–I25) or sudden car-
diac death (ICD-10 codes R96.0–1).
Nonfatal CHD was deﬁned as nonfatal
myocardial infarction (ICD-10 code I21),
unstable angina (ICD10 code I20.0), per-
cutaneous coronary intervention (PCI),
and/or coronary artery bypass grafting
(CABG). Stroke was deﬁned as fatal or
nonfatal stroke (ICD10 codes I61, I63,
I64, and I67.9).
All CVD end points were retrieved by
data linkage with the Swedish Cause of
Death Register and the Hospital Dis-
charge Register (National Board of Health
and Welfare, Sweden), which is an efﬁ-
cient validated alternative to revised
hospital discharge notes and death certif-
icates (16,17). In total, 1,482 ﬁrst inci-
dent fatal/nonfatal CVD events occurred,
based on 58,342 person-years during
mean 5.64 years of follow-up.
Statistical methods
Cox regression analysis was used to esti-
mate hazard ratios (HRs) with 95% CI for
nine predictors of CVD, adjusted for each
other. Forward, backward, and score se-
lectionshowedbestmodelﬁtwithallnine
predictors included. Maximum likeli-
hood estimation showed no interaction
between the predictors. The proportional
hazard assumption was conﬁrmed for all
predictors with the Kolmogorov-type
Supremum test and with the test of all
time-dependent covariates simulta-
neously. HRs were used as coefﬁcients
(1–9)formodelingariskequation.The
baseline hazard for year 5 (q5) was also
assessed, when all nine covariates were
given the value 0.
Survival analysis was used to calcu-
late the observed survival probability rate
of CVD for years 1–5 with 95% CI (Fig.
1). Calibration of the risk equation was
estimated with the ratio of observed sur-
vival rate to predicted rate and with the
Hosmer-Lemeshow test assessing good-
ness of ﬁt. Discriminating capacity of the
risk equation was estimated with the re-
ceiver operator curve statistic (c statistic)
and with sensitivity and speciﬁcity ac-
cording to cutoff levels of risk.
The accuracy of the risk equation was
also tested in two randomly selected sub-
groups, A and B, with 5,823 patients in
each subgroup. A 5-year risk equation
was generated in subgroup A, according
to HRs for the nine predictors. This equa-
tion was used in subgroup B to estimate
predicted survival rate for comparison
with observed rate.
Furthermore, in all patients, the nine
predictor HRs and baseline hazard for
year 4 (q4) were used to generate an
equation for 4-year CVD risk. This
equation was applied in patients newly
registered in the NDR 1999, and cali-
bration (observed 4-year CVD rate to
Figure 1—Observed survival probability rate with 95% CIs and modeled survival rate for fatal/
nonfatal CVD in 11,646 type 2 diabetic patients.
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statistic) were estimated.
All statistical analyses were per-
formed with SAS (version 9.1; SAS Insti-
tute, Cary, NC). P  0.5 was considered
signiﬁcant.
RESULTS— Clinical characteristics at
baseline, presented as mean values  SD
or proportions, are shown in Table 1,
which also gives values for the nine pre-
dictors used in the risk equation as de-
scribed in the text. The adjusted HRs for
ninepredictorsoffatal/nonfatalCVDwith
Cox regression analysis were all statisti-
cally signiﬁcant (P  0.0001, except for
BMI P  0.0016). These HRs (1–9)
with 95% CI were 1.066 (1.057–1.075)
for a 1-year increase in onset age, 1.538
(1.381–1.712) for male sex, 1.087
(1.076–1.097) for a 1-year increase in di-
abetes duration, 1.117 (1.074–1.161) for
a 1% increase in A1C, 1.017 (1.006–
1.028) for a 1-unit increase in BMI, 1.278
(1.143–1.428) for antihypertensive
drugs, 1.007 (1.004–1.010) for a
1-mmHg increase in systolic blood pres-
sure, 1.314 (1.146–1.507) for lipid-
lowering drugs, and 1.492 (1.314–
1.694) for smoking. The baseline hazard
(q5) was 0.00013 (0.00003–0.00022).
A risk equation was created for esti-
mation of the 5-year risk of CVD, using
q and the HRs for the nine predictors
(1–9):
5-year risk (CVD)  (1  exp[{q5
 1
ageduration  2
sex  3
duration
 4
A1C  5
BMI  6
antihypertensive drugs
 7
systolic blood pressure  8
lipid-lowering drugs
 9
smoker}])  100
1 expresses the HR for age at onset of
diabetes (age minus duration, in years).
Valuesoftheninepredictorswereapplied
to the equation as described in Table 1: 1
for men and 0 for women; 1 for presence
of antihypertensive drugs, lipid-lowering
drugs, and smoker and 0 otherwise.
Figure 1 shows the observed survival
probability rate for fatal/nonfatal CVD
during 5 years in all patients. The mod-
eled survival rate for CVD is also shown,
estimated with the NDR risk equation.
The modeled survival rate is lying very
close to the observed rate, well within its
95% CI, and the ratio of observed to pre-
dicted rate was 0.999. The Hosmer-
Lemeshow test, comparing observed and
predicted risk within 10 risk deciles,
demonstrated excellent goodness of ﬁt
with a nonsigniﬁcant 
2 statistic of 4.29
(P  0.83).
Furthermore, after we divided all pa-
tients into subgroups with predicted risk
5%, 5–9.9, 10–14.9, 15–19.9, 20–
24.9, and 25–29.9%, predicted survival
rates were very close to observed rates in
all subgroups and well within their 95%
CIs (mean ratio of observed to predicted
rate 0.999, range 0.983–1.011). Discrim-
ination according to the C statistic was
0.70. The proportion of patients with
CVDonfollow-upwhohadpredictedrisk
10%was78%(sensitivity),andthepro-
portion without CVD events with a risk
15% was 75% (speciﬁcity).
The modeled survival rate for CVD in
subgroup B (randomly selected half-
part), estimated with the risk equation
created in subgroup A, was also found to
lie close to the observed survival rate in
subgroup B and within its 95% CI. The
modeled 5-year survival rate in subgroup
B was 87.7%, and the observed rate (95%
CI) was 87.6% (86.7–88.4%), with a ra-
tio of 0.998. The C statistic in subgroup B
was 0.69.
To illustrate the use of the NDR risk
equation, consider a male type 2 diabetic
patient at age 58 years, with diabetes du-
ration of 5 years, A1C of 8.0%, BMI of 32
kg/m
2, and systolic blood pressure 150
mmHg, who was being treated with anti-
hypertensives and not with lipid-
lowering drugs and was a nonsmoker:
5-year risk (CVD)  (1  exp[{0.00013
 1.066
585  1.538
1  1.087
5
 1.117
8  1.017
32  1.278
1
 1.007
150 1.314
0  1.4920}])
 100  12.7%
Table 2 shows the 5-year risk of fatal/
nonfatal CVD estimated with the NDR
risk equation in the study sample, free
from previous CVD. In all patients aged
18–70years,themean5-yearriskofCVD
was 12.0%, and the percentages with
risks 10 and 15%, respectively, were
54 and 29%. In subgroups aged 41–50,
51–60, 61–65, and 66–70 years, per-
centages with risk 10% were, respec-
tively, 4.2, 36.8, 77.3, and 94.3%.
Application of an equation for 4-year
risk of CVD from the study sample (using
all predictor HRs together with baseline
hazard q4  0.00010) to another sample
of 3,068 type 2 diabetic patients from the
NDR (newly registered in 1999, followed
during 4 years based on 11,879 person-
years, 261 CVD events, and no previous
CVD) demonstrated good calibration: ra-
tio of observed CVD rate to predicted risk
0.96 in all patients and 0.91–1.02 to
0.98–0.92 in subgroups with risk from
5% to 15%; all predicted risks were
well within the 95% CIs of observed rates
(Table 2). The C statistic was 0.69 in all
patients.
CONCLUSIONS — This study pre-
sents a new diabetes-speciﬁc risk equa-
tion for estimation of the absolute 5-year
Table 1—Baseline characteristics in 11,646 type 2 diabetic patients aged 18–70 years, used as predictors of CVD in the NDR risk equation
All patients Men Women Values used in the risk equation
n 11,646 6,628 5,018
Age at onset of diabetes 50.7  9.8 50.3  9.4 51.3  10.3 Age  duration: years
Duration of diabetes 7.5  6.6 7.5  6.6 7.5  6.7 Years
A1C 7.6  1.4 7.6  1.3 7.7  1.4 %
BMI 29.2  5.1 28.7  4.5 29.8  5.8 kg/m
2
Systolic blood pressure 144.5  18.1 143.9  17.4 145.2  19.0 mmHg
Male/female sex (%) 56.9/43.1 — — 1 for men, 0 for women
Antihypertensive drugs (%) 44.7 44.0 45.7 1 for drug presence, 0 otherwise
Lipid-lowering drugs (%) 13.0 13.1 12.8 1 for drug presence, 0 otherwise
Smokers (%) 17.8 18.5 16.8 1 for current smoker, 0 otherwise
Data are means  SD or proportions.
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that was developed with use of a large
sample of type 2 diabetic patients from
the normal patient population nation-
wide. This NDR risk equation includes as
predictorseighteasilyestimatednonlabo-
ratoryclinicalcharacteristicsandonenec-
essary nonfasting blood sample, A1C,
enabling quickly performed calculations
of the 5-year CVD risk at patient visits in
daily clinical practice.
Calibration of this risk equation was
foundtobeexcellentwhenassessedasthe
ratio of observed to predicted survival
rates, and the modeled survival rate was
found to lie very close to the observed
survival rate (Fig. 1). The Hosmer-
Lemeshow test, comparing observed and
predicted risk, demonstrated excellent
goodness of ﬁt. The discriminative capac-
ity of the model was also sufﬁcient, with a
Cstatisticof0.70.Discriminationwasfur-
ther veriﬁed by a sensitivity of 78% with
predicted risk of 10% and a speciﬁcity
of 75% with risk of 15%.
As emphasized in a recent review
(18), both calibration and discrimination
canneverbeperfectwhenoneisassessing
risk equations, and calibration is more
valuable and important for the accurate
assessmentofriskthantheCstatistic.Dis-
crimination would be perfect if all pa-
tients had, e.g., risk of 11%, and all
nonpatients had risk of 10% but would
not be helpful for treatment decisions
based on risk assessment. With an aver-
ageriskandaspreadofthedistributionas
in this sample, the maximum C statistic
might in fact be 	0.75 (18). The most
important aspect for a risk equation is its
ability to accurately stratify subjects into
higher or lower risk categories of impor-
tance for clinical treatment (18). We
found accurate calibration in subgroups
with5-yearCVDriskintervalsfrom5%
up to 25–30%, with an excellent match
betweenpredictedandobservedrate.The
accuracyofthemodelwasfurtherveriﬁed
when a risk equation with the same pre-
dictors was modeled in a randomly se-
lected half-part of the sample and then
applied in the remaining half-part with
excellent calibration regarding observed
and modeled survival rates.
The data for type of hypoglycemic
treatment, diabetes duration, A1C, BMI,
blood pressure, and antihypertensive and
lipid-lowering drugs were considered re-
liable in this study. The data for smoking
might be somewhat biased because of un-
der-reporting by patients or examiners.
CVD events retrieved from the National
Cause of Death and Hospital Discharge
Registers were also reliable, according to
previous validations of reporting to these
registers (16,17). The upper age of pa-
tients included was limited to 70 years to
avoid the risk of less precise end point
diagnosisinolderpatients.Thedeﬁnition
of type 2 diabetes used here should ex-
clude most of the younger patients with
possible late autoimmune disease of the
adult,asonly1%hadonsetage30years
and 3% had onset age 40 years. The
large numbers of person-years and CVD
events constitute a major strength of the
study. The fact that patients were col-
lected from the general Swedish diabetes
population, by experienced physicians
and nurses according to NDR guidelines
fordatareportingatmorethanone-fourth
of all primary care centers and more than
three-fourths of all hospital diabetes clin-
ics nationwide, with reported patients
ranging up to 200 and 300 patients per
unit, should make the study sample rea-
sonablyrepresentative.Therewerenoex-
clusions attributable to the presence or
absence of risk factors or comorbidities,
as is often present in randomized con-
trolled trials with limitations owing to
strict inclusion and exclusion criteria that
may limit their applicability to the com-
mon patient populations.
What does this new NDR risk equa-
tion in type 2 diabetic patients add, com-
paredwiththepreviouslyderivedUKPDS
risk engine? The UKPDS risk equations
estimate the 10-year risks of myocardial
infarction, stroke, and CVD and were de-
veloped from a randomized controlled
trialwithbaseline1977–1991,in	4,000
patientsaged25–65yearswithnewlyde-
tectedtype2diabetes,usingseveralblood
tests: A1C and total and HDL cholesterol
(6–8). Other previous risk models, using
severalbloodtestsaspredictors,havealso
presented 10-year estimates of CVD risk
(2–4). Comparatively, this NDR risk
equation is based on a later sample in
1998–2003, which is large enough to al-
lowtheuseofa5-yearestimateofriskand
is probably more accurate than 10-year
estimates of risk for the interval from
baseline data and more useful from a pa-
tient treatment perspective than events in
the far future, as emphasized in a recent
review (9).
Although this study was observa-
tional, it should reﬂect the normal type 2
diabetic patient population in general
care, also allowing the inclusion of pa-
tients with various durations of diabetes
and age up to 70 years. Other recent risk
scores have chosen to estimate CVD risk
(1–3,8), but estimating CVD by combin-
ing CHD and stroke in this NDR model
also allowed for the inclusion of patients
with acute coronary syndromes and pa-
Table2—Predicted5-yearfatal/nonfatalCVDriskinstudypatientswithbaseline1998andpredicted4-yearCVDriskwithobservedCVDrate
in a separate sample from the NDR with baseline 1999 and followed during 4 years, estimated with the NDR risk equation
5-year risk n
5-year risk
mean  SD 10% (%) 15% (%) 4-year risk n
4-year risk
mean  SD
Observed rate %
(95% CI*) Ratio†
Category Category
All 11,646 12.0  7.5 53.6 28.8 All 3,068 8.8  6.1 8.5 (7.5–9.5) 0.96
Men 6,628 13.5  8.1 60.3 36.3 Men 1,791 10.0  6.6 9.8 (8.5–11.2) 0.98
Women 5,018 10.1  6.2 44.8 18.9 Women 1,277 7.2  5.0 6.7 (5.3–8.0) 0.92
Age-groups (years) Intervals‡
41–50 1,449 4.8  2.4 4.2 0.5 5.0% 945 3.0  1.2 2.8 (1.7–3.8) 0.91
51–60 4,327 9.4  4.3 36.8 10.6 5–9.9% 1,066 7.3  1.4 7.4 (5.8–9.0) 1.02
61–65 2,571 14.6  5.8 77.3 40.2 10–14.9% 606 12.3  1.4 12.0 (9.4–14.7) 0.98
66–70 2,756 19.4  7.4 94.3 67.5 15.0% 451 20.1  5.1 18.4 (14.8–22.0) 0.92
*CI of observed CVD rate. †Ratio: observed 4-year CVD rate to predicted 4-year CVD risk. ‡Intervals of 4-year risk of ﬁrst incident fatal/nonfatal CVD. This risk was
estimated with the same predictor HRs as for the 5-year risk, in a separate later NDR sample with baseline 1999 and followed up during 4 years.
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PCI or CABG procedures before the oc-
currence of manifest myocardial infarc-
tion.Antihypertensiveandlipid-lowering
drugs were included as risk markers of
hypertensionanddyslipidemia.Although
ideally blood lipids might be included,
this model allows quick risk estimation
with the use of nonlaboratory clinical
characteristics easily available in daily
practice, and only one nonfasting blood
test, A1C, was needed. The inclusion of
BMI in the NDR risk equation should also
be of value, as many diabetic patients are
overweight or obese, and this trend is in-
creasing. Furthermore, elevated BMI val-
ues should fairly well reﬂect dyslipidemia
and should also serve as a surrogate
marker for increased insulin resistance.
Similarly, a recently developed more sim-
ple risk model from the Framingham
Heart Study used BMI instead of total
and HDL cholesterol and showed that
this model could predict CVD risk rea-
sonably well (19). Overweight and obe-
sity were recently found to be strong
independent determinants of CHD in a
meta-analysis of 
300,000 subjects
(20), and this ﬁnding has also been ver-
iﬁed in a recent study of type 2 diabetic
patients in the NDR (K.E.-O. et al.,
2008, unpublished observations).
A target level of 15% for the 10-year
risk of myocardial infarction has been
suggestedbytheBritishNationalInstitute
of Clinical Guidance (21), and SCORE
has recommended a level of 5% for the
10-year risk of fatal CVD (2). We have
chosen a 5-year risk 10% for fatal/
nonfatalCVDasthetargetlevel,withsen-
sitivity of 78% at this level, and values for
54% of all patients were greater than this
level in this study. As expected, age had a
strong inﬂuence, as only 4% aged 50
years had values greater than this target.
One-third of patients aged 51–60 years
hadrisk10%,emphasizingtheneedfor
more aggressive multifactorial treatment
in these patients, as indicated in the
STENO-2 study in this age interval (22).
Of patients aged 61–65 years, 77% had
risk 10%, strongly indicating a need for
intensiﬁedmultifactorialtreatmentinthis
age-group.
Application of a 4-year risk equation
from the study sample in a later separate
NDRsamplefollowedduring4yearscon-
ﬁrmedtheaccuracyoftheNDRriskequa-
tion, with good calibration according to
the ratio of observed CVD rate/predicted
risk.
In summary, the NDR risk equation
has been elaborated as a more simpliﬁed
and easily applied tool in daily practice,
also allowing for the use of BMI as a
marker of lifestyle. It was derived from a
largeobservationalprospectivestudy,ob-
tained from the normal patient popula-
tion with an age span of 18 to 70 years.
The estimate of 5-year risk of CVD might
be preferable to that of 10-year risk, and
the estimated risk also includes patients
withacutecoronarysyndromesandthose
treated with PCI or CABG. This new risk
model should preferably be evaluated in
other cohorts.
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